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Abstract
Background: Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic
biomarkers and pathogenic factors for neuromyelitis optica (NMO). However, AQP4-IgG are absent in 5-40% of all
NMO patients and the target of the autoimmune response in these patients is unknown. Since recent studies
indicate that autoimmune responses to myelin oligodendrocyte glycoprotein (MOG) can induce an NMO-like
disease in experimental animal models, we speculate that MOG might be an autoantigen in AQP4-IgG
seronegative NMO. Although high-titer autoantibodies to human native MOG were mainly detected in a subgroup
of pediatric acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) patients, their role in NMO
and High-risk NMO (HR-NMO; recurrent optic neuritis-rON or longitudinally extensive transverse myelitis-LETM)
remains unresolved.
Results: We analyzed patients with definite NMO (n = 45), HR-NMO (n = 53), ADEM (n = 33), clinically isolated
syndromes presenting with myelitis or optic neuritis (CIS, n = 32), MS (n = 71) and controls (n = 101; 24 other
neurological diseases-OND, 27 systemic lupus erythematosus-SLE and 50 healthy subjects) for serum IgG to MOG
and AQP4. Furthermore, we investigated whether these antibodies can mediate complement dependent
cytotoxicity (CDC). AQP4-IgG was found in patients with NMO (n = 43, 96%), HR-NMO (n = 32, 60%) and in one CIS
patient (3%), but was absent in ADEM, MS and controls. High-titer MOG-IgG was found in patients with ADEM (n =
14, 42%), NMO (n = 3, 7%), HR-NMO (n = 7, 13%, 5 rON and 2 LETM), CIS (n = 2, 6%), MS (n = 2, 3%) and controls
(n = 3, 3%, two SLE and one OND). Two of the three MOG-IgG positive NMO patients and all seven MOG-IgG
positive HR-NMO patients were negative for AQP4-IgG. Thus, MOG-IgG were found in both AQP4-IgG seronegative
NMO patients and seven of 21 (33%) AQP4-IgG negative HR-NMO patients. Antibodies to MOG and AQP4 were
predominantly of the IgG1 subtype, and were able to mediate CDC at high-titer levels.
Conclusions: We could show for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-
NMO exhibit a MOG-IgG mediated immune response, whereas MOG is not a target antigen in cases with an AQP4-
directed humoral immune response.
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Neuromyelitis optica (NMO), a severe inflammatory
demyelinating disorder, has gained increasing interest
since the discovery of serum NMO-IgG autoantibodies
targeting the aquaporin-4 (AQP4) water channel protein
[1,2]. The detection of this highly specific biomarker
resulted in the incorporation of the NMO-IgG serostatus
in the diagnostic criteria of NMO [3]. An early differentia-
tion from multiple sclerosis (MS) is highly important, due
to differences in prognosis and therapy of NMO patients.
The target antigen AQP4 is localized on astrocytic endfeet
[4] and is expressed as full length M1 or shorter M23
AQP4 isoform [5,6]. Recently, serum anti-AQP4 antibo-
dies were shown to bind primarily to the shorter M23
AQP4 isoform [7-9], which is of high diagnostic relevance
due to an increased sensitivity of NMO-IgG analysis. Anti-
bodies to AQP4 are also frequently detected in so called
“High-risk NMO” (HR-NMO) patients not fulfilling all
diagnostic criteria for NMO, who present with NMO-
associated symptoms like recurrent optic neuritis (ON) or
longitudinally extensive transverse myelitis (LETM)
extending more than three vertebral segments [10].
NMO-IgG seropositivity was shown to be predictive for a
poor visual outcome and the development of NMO in
patients with recurrent ON [11,12]. Furthermore, the
detection of AQP4-IgG in patients with a first episode of
LETM extending ≥ three vertebral segments was asso-
ciated with further relapses of LETM or ON, in some
cases even within half a year [13]. Therefore, NMO and
HR-NMO patients (recurrent ON or monophasic/recur-
rent LETM) are also classified as NMO-spectrum disor-
ders (NMOSD) [10]. However, AQP4-IgG are missing in
5-40% of these patients, depending on the immunoassay
used [9,12,14-16]. It is not yet known whether autoantibo-
dies to other central nervous system (CNS) specific anti-
gens are present in patients with NMO and HR-NMO
[17].
Recent experimental studies indicated that myelin oligo-
dendrocyte glycoprotein (MOG), a glycoprotein localized
on the outer surface of the myelin sheath and oligodendro-
cytes [18], might be a target antigen in NMO. Two in vivo
studies demonstrated spontaneous development of NMO-
like symptoms with severe opticospinal experimental auto-
immune encephalomyelitis (EAE) in a double-transgenic
opticospinal EAE (OSE) mouse model expressing T cell
and B cell receptors specific for MOG [19,20]. This mouse
strain closely resembles human NMO by exhibiting proto-
typical inflammatory demyelinating lesions in the optic
nerve and spinal cord. Furthermore, the animals were
found to exhibit highly positive serum MOG-IgG1 antibo-
dies [19]. Additionally, there are several reports demon-
strating the induction of an NMO-like disease following
immunization of certain rat strains with MOG [21-23].
Whereas in humans anti-MOG antibodies in MS have
been extensively investigated, their role in NMO has not
been adressed so far. High-titer IgG autoantibodies to con-
formational epitopes of MOG (MOG-IgG) were detected
in a subgroup of pediatric patients with acute disseminated
encephalomyelitis (ADEM) and MS, but rarely in adult-
onset MS [24-29]. A possible role of MOG-IgG antibodies
in NMO-related diseases is supported by recent findings
of our group, demonstrating an increased frequency of
MOG-IgG in pediatric patients with recurrent ON com-
pared to monophasic ON subjects (Rostasy K, Mader S,
Schanda K, Huppke P, Gärtner J, Kraus V, Karenfort M,
Tibussek D, Blaschek A, Kornek B, Leitz S, Schimmel M,
Di Pauli F, Berger T, Reindl M: Anti-MOG antibodies in
children with optic neuritis, in press). However, so far only
one study using the bacterially expressed extracellular
domain of MOG as antigen described the occurrence of a
humoral immune response to MOG in four NMO patients
[30].
Therefore, we decided to investigate the frequency and
titer levels of IgG antibodies to MOG and AQP4 in a mul-
ticenter study of patients with CNS demyelinating diseases
using a live cell staining immunofluorescence assay with
HEK-293A cells transfected with either AQP4 or MOG
[9,24]. In addition, we analyzed the IgG subtypes of anti-
bodies directed to MOG and AQP4 and their ability to
activate the complement cascade in a subset of patients.
Results
Serum AQP4-IgG and high-titer MOG-IgG antibodies in
different disease groups
Using our assay with M23 AQP4 transfected HEK-293A
cells, we detected significantly increased frequencies of
serum AQP4-IgG in NMO (n = 43, 96%) and HR-NMO
(n = 32, 60%; Table 1). Median AQP4-IgG titers of seropo-
sitive patients were 1:1,280 (1:40-1:40,960) in NMO and
1:1,280 (1:20-1:20,480) in HR-NMO (Figure 1). In addi-
tion, AQP4-IgG (titer 1:640) was detected in one patient
with clinically isolated syndrome (CIS) presenting with
myelitis. AQP4-IgG antibodies were absent in two patients
with NMO (4%), 21 patients with HR-NMO (40%), 31 CIS
patients (97%) and all patients with ADEM and MS as well
as all controls (CTRL) including patients with systemic
lupus erythematosus (SLE), other neurological diseases
(OND) and healthy individuals (Table 1).
In addition to AQP4-IgG, we analyzed antibodies direc-
ted to natively folded human MOG expressed on the sur-
face of human cells in the same set of patients (Table 1
and Figure 1). The frequency of high-titer (≥ 1:160)
serum MOG-IgG antibodies was significantly increased
in patients with ADEM (n = 14, 42%). However, high-
titer MOG-IgG were also found in patients with NMO
(n = 3, 7%), HR-NMO (n = 7, 13%), CIS (n = 2, 6%), MS
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Page 2 of 14(n = 2, 3%) and CTRL (3, 3%) (Table 1, Figure 1). Median
MOG-IgG titers of seropositive patients were 1:2,560
(1:160-1:2,560) in NMO, 1:2,560 (1:640-1:5,120) in HR-
NMO, 1:2,560 (1:160-1:20,480) in ADEM, 1:640 and
1:5,120 in CIS, 1:160 and 1:160 in MS and 1:320 (1:160-
1:640) in CTRL (Figure 1 and Table 1).
The clinical characteristics of MOG-IgG positive
patients with NMO, HR-NMO and CIS are shown in
Table 2. The MOG-IgG positive NMO patients con-
sisted of two AQP4-IgG seronegative patients (a two
year old female child and a 56 year old male), both with
a MOG-IgG titer of 1:2,560, and one patient (a 39 year
old woman) who was double positive for both, MOG-
IgG (titer 1:160) and AQP4-IgG (titer 1:1,280). Within
the HR-NMO group, seven of 21 (33%) AQP4-IgG
negative patients were positive for high-titer MOG-IgG
(Table 1 and 2). These seven patients included five
patients with recurrent ON and two patients with
monophasic LETM. The spinal magnetic resonance
image (MRI) of a high-titer MOG-IgG positive patient
presenting with LETM (patient number 10, Table 2) is
shown in Figure 2. Both MOG-IgG seropositive CIS
patients presented with monophasic ON and were nega-
tive for AQP4-IgG (Table 2).
Furthermore, MOG-IgG was detected at threshold
levels (1:160) in two of 71 MS patients (secondary pro-
gressive MS and pediatric MS). Within the CTRL
cohort, MOG-IgG was observed in two of 27 SLE
patients (1:320 and 1:160) and one of 24 OND patients
(1:640, pediatric patient with genetically confirmed
citrullinemia, presenting with encephalopathy and multi-
focal neurological deficits [24]), whereas all 50 healthy
controls were MOG-IgG negative.
Analysis of AQP4-IgG and MOG-IgG mediated
complement activation using MOG or AQP4 transfected
HEK-293A cells
We additionally analyzed a subset of 15 AQP4-IgG positive
samples for the presence of IgG1-IgG4 isotypes, and found
that AQP4-IgG antibodies consisted primarily of the IgG1
isotype in 13 patients (87%), while two patients presented
with IgG1 and IgG3 antibodies (13%). In contrast to anti-
AQP4 autoantibodies, analysis of IgG1-IgG4 isotypes
revealed that human serum MOG-IgG antibodies of 15
investigated patients consisted only of the IgG1 isotype.
Using our live cell staining immunofluorescence assay
(IF) assay, we found that human AQP4-IgG are able to
activate the complement cascade at high-titers, leading to
the formation of the terminal complement complex
(TCC). The resultant TCC was exclusively detected on the
surface of AQP4-EmGFP transfected cells (Figure 3).
Furthermore, NMO antibody mediated complement acti-
vation resulted in complement-dependent lysis of AQP4
transfected cells, which could be demonstrated via DAPI
staining of dead cells (Figure 3). Scanning electron micro-
scopy analysis revealed increased apoptosis characterized
Table 1 Serum IgG antibodies directed to AQP4 and MOG (high-titer MOG-IgG antibodies at ≥ 1:160) in patients with
CNS demyelinating diseases
Disease Number Females
1 Age (y)
2 AQP4-IgG
1,3 MOG-IgG
1,3
NMO 45 41 (91%) * 50 (2-80) 43 (96%) § 3 (7%)
1,280 2,560
(40-40,960) (160-2,560)
HR-NMO 53 34 (64%) 48 (13-74) 32 (60%) § 7 (13%)
1,280 2,560
(20-20,480) (640-5,120)
ADEM 33 20 (61%) 12 (2-52) § 0 (0%) 14 (42%) §
- 2,560
(160-20,480)
CIS 32 22 (69%) 34 (5-57) + 1 (3%) 2 (6%)
640 (640; 5,120)
MS 71 43 (61%) 40 (14-66) 0 (0%) 2 (3%)
(160; 160)
CTRL 101 79 (78%) 43 (14-84) 0 (0%) 3 (3%)
320
(160-640)
p-value 0.003 < 0.001 < 0.001 < 0.001
P-value: groups were compared using
1 Chi-Square test with Fisher’s exact post-hoc test and
2 Kruskal-Wallis test with Dunn’s post-hoc test (data are shown as
median with range);
3 median titer level (range) of MOG-IgG or AQP4-IgG seropositive samples; * statistically different from HR-NMO, ADEM and MS; + statistically
significant from NMO, HR-NMO and ADEM; § statistically significant from all other groups (p-values were corrected for multiple comparisons). Abbreviations: y =
years, NMO = Neuromyelitis optica, HR-NMO = High-risk NMO, ADEM = acute disseminated encephalomyelitis, CIS = clinically isolated syndrome, MS = multiple
sclerosis, CTRL = controls.
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Page 3 of 14Figure 1 Serum MOG-IgG and AQP4-IgG antibody titer levels in CNS demyelinating diseases and controls. Serum AQP4-IgG (upper
panel) were exclusively detected in serum samples of patients with NMO and HR-NMO and one CIS patient, but not in any subjects with ADEM,
MS and CTRL. Serum MOG-IgG (lower panel) were present at highest titers (≥ 1:160, indicated by a dotted vertical line) in a cohort of patients
with ADEM, AQP4-IgG seronegative HR-NMO (pink squares) and in both AQP4-IgG seronegative NMO subjects (blue squares, both at a MOG-IgG
titer of 1:2,560) as well as in two CIS samples (green triangles). One patient (NMO) was found to be double positive for MOG-IgG (blue square at
the threshold level of 1:160, lower panel) and AQP4-IgG (blue square at a titer of 1:1,280; upper panel). Coloured icons indicate individual
patients in the upper and lower panel.
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Page 4 of 14Figure 2 Longitudinally extending spinal cord lesions in a high-titer MOG-IgG seropositive and AQP4-IgG seronegative patient. Sagittal
T2 weighted MRI of a lesion extending over 8 vertebral segments (upper left) in a 49 year old female patient (Table 2, patient number 10).
Transversal T2 weighted image (lower left) shows the extension over the whole cross-sectional area of the spinal cord. Contrast enhanced T1
weighted images (sagittal, upper right and transversal, lower right) show scattered contrast enhancement in the lesion.
Table 2 Clinical characteristics of high-titer MOG-IgG seropositive patients with NMO (n = 3), HR-NMO (n = 7) and CIS
(n = 2)
No./Sex/Age (y) Diagnosis MOG-IgG
titer
AQP4-IgG
titer
relapses ON myelitis LETM Cerebral MRI lesions MOG -TCC
1/F/2 NMO 1:2,560 negative 2 yes yes yes no pos
2/F/39 NMO 1:160 1:1,280 4 yes yes yes no n.a
3/M/56 NMO 1:2,560 negative 2 yes yes yes n.a pos
4/F/28 HR-NMO (rON) 1:5,120 negative 2 yes no no no pos
5/M/13 HR-NMO (rON) 1:5,120 negative 3 yes no no no pos
6/F/48 HR-NMO (rON) 1:2,560 negative 16 yes no no no pos
7/F/46 HR-NMO (rON) 1:640 negative 3 yes no no no neg
8/M/32* HR-NMO (rON) 1:640 negative 11 yes no no no neg
9/F/43 HR-NMO (LETM) 1:2,560 negative 1 no yes yes no pos
10/F/49* HR-NMO (LETM) 1:640 negative 1 no yes yes no pos
11/F/5 CIS (ON) 1:5,120 negative 1 yes no no no pos
12/M/13 CIS (ON) 1:640 negative 1 yes no no no neg
Abbreviations: No. = patient number, F = female, M = male, y = years, MRI = magnetic resonance image, NMO = Neuromyelitis optica, HR-NMO = High-risk NMO,
rON = recurrent optic neuritis, ON = optic neuritis, LETM = longitudinally extensive transverse myelitis, CIS = clinically isolated syndrome, MOG-TCC = MOG-IgG
dependent terminal complement complex, n.a = not available. * paired serum and CSF samples were available from patient 8 and 10. The corresponding CSF
was found to be negative for AQP4-IgG as well as for MOG-IgG (CSF was analyzed undiluted and diluted 1:2 as previously described [48]).
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Page 5 of 14by a detachment of the cell layer (Figure 4). No TCC for-
mation was observed using AQP4-IgG positive serum
samples supplemented with inactive complement. Incuba-
tion of AQP4 transfected cells with active complement
without serum or with serum samples of AQP4-IgG nega-
tive patients supplemented with active complement did
not result in complement dependent cytotoxicity (CDC;
additional file 1). To verify the antibody mediated localiza-
tion of the TCC, cells were transfected using AQP4 with-
out the EmGFP fusion protein (Figure 5). In this setting,
the membrane attack complex co-localized with human
AQP4-IgG. Furthermore, complement-dependent interna-
lization of AQP4-IgG antibodies was observed.
M O G - I g Ga n t i b o d i e sw e r ea b l et oi n d u c et h ec o m p l e -
ment cascade in vitro i nt h es a m em a n n e ra ss h o w n
for AQP4-IgG antibodies. Using MOG transfected cells
with and without EmGFP fusion protein, we could
clearly show a co-localization of the TCC with MOG-
EmGFP (Figure 6). The membrane attack complex
resulted in an internalization of anti-MOG antibodies
and complement-mediated lysis of MOG transfected
cells (Figure 6, additional file 2). In order to exclude
an unspecific activation of complement by MOG itself
[31], MOG transfected cells were incubated with active
complement in the absence of serum (additional file
2). In contrast to high-titer MOG-IgG positive serum
s a m p l e so fA D E M ,N M O ,H R - N M Oa n dC I Sp a t i e n t s ,
low-titer and MOG-IgG negative samples did not lead
to CDC in the presence of active complement (addi-
tional file 2).
Figure 3 Serum AQP4-IgG antibodies of an NMO patient activate the complement cascade in the presence of active complement
resulting in the deposition of the terminal C5b-9 complement complex. A. Formation of the terminal complement complex (TCC, red) on
the surface of M23 AQP4-EmGFP expressing HEK-293A cells (green) following addition of a heat- inactivated AQP4-IgG positive serum sample
(titer of 1:10,240). The membrane attack complex resulted in lysis of AQP4-expressing cells (DAPI, blue). B. No antibody mediated complement
activation was detectable following incubation of the same heat-inactivated AQP4-IgG positive NMO serum sample supplemented with inactive
complement (TCC, red). Images are representative of similar staining patterns observed in independent complement activation assays of the 27
AQP4-IgG positive patients (Table 3). Images are shown in 20 × (A-upper panel and B) and 63 × (A-lower panel) magnification.
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Page 6 of 14Figure 5 Co-localization of the terminal complement complex (TCC) with an NMO patient’ss e r u mA Q P 4 - I g G . A. The heat-inactivated
serum sample of an AQP4-IgG positive NMO patient (titer 1:5,120) was added to M23 AQP4 transfected cells (without EmGFP fusion protein) in
the presence of either active or inactive complement. Complement-mediated cytotoxicity (TCC, green) was only detectable after addition of
active complement. Furthermore, the TCC co-localized (merged) with the antibodies directed to AQP4 (AQP4-IgG, red) resulting in lysis of the
AQP4 transfected cells (DAPI staining, blue). The activation of the complement cascade was accompanied by an internalization of AQP4-IgG,
resulting in an attenuated signal (red). B. An AQP4-IgG negative serum sample of an SLE patient resulted in no formation of the TCC in the
presence of active complement.
Figure 4 Scanning electron microscopy of serum AQP4-IgG mediated complement activation. Following incubation of AQP4 transfected
HEK-293A cells with an NMO serum (AQP4-IgG titer: 1:10,240) and either active or inactive complement, the cells were investigated via scanning
electron microscopy (1,000 × magnification). NMO serum supplemented with active complement resulted in increased apoptosis (shown by the
detached cells, left panel). In contrast, the cell layer of NMO serum supplemented with inactive complement remained largely preserved (right
panel). Images are representative of similar observations in independent complement activation assays.
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Page 7 of 14AQP4-IgG and MOG-IgG directed complement-mediated
cytotoxicity in patients with CNS demyelinating diseases
Next, we grouped patients with NMO (n = 23), HR-
NMO (n = 33), ADEM (n = 19), CIS (n = 14), MS (n =
10) and CTRL (n = 14) based on their ability to initiate
MOG-IgG or AQP4-IgG dependent complement activa-
tion (TCC AQP4-/MOG-, TCC AQP4+/MOG- or TCC
AQP4-/MOG+; Table 3 and additional file 3). The selec-
tion of patients for the analysis of complement-mediated
cytotoxicity was based on the availability of serum sam-
ples and the use of samples which are representative for
our entire study population. We found no significant
differences in the three groups regarding clinical para-
meters, such as ON, myelitis, LETM, disease duration or
relapse frequency (data not shown).
Overall, AQP4-IgG mediated complement activation
was observed exclusively in 27 patients positive for
AQP4-IgG with a median titer of 1:1,280 (ranging from
1:160 to 1:20,480; Table 3 and additional file 3), consist-
ing of NMO, HR-NMO and one CIS patient. In con-
trast, samples of patients with lower AQP4-IgG
antibody titers and all investigated serum samples of
AQP4-IgG negative CNS demyelinating diseases and
controls were not able to activate the complement cas-
cade on the surface of AQP4-expressing HEK-293A
cells (Table 3 and additional file 3).
Similarly, assembly of the TCC was observed on the
surface of MOG transfected cells after incubation with
serum samples having a median MOG-IgG titer level of
1:2,560 (ranging from 1:640 to 1:20,480), as shown in
Figure 6 Serum MOG-IgG mediated complement activation. A. High-titer MOG-IgG antibodies of an ADEM patient (titer 1:20,480) can
activate the complement system on MOG expressing HEK-293A cells (MOG-EmGFP, green), resulting in TCC formation (red) and cell lysis (blue)
following addition of active complement. B. No TCC formation was observed with the MOG-IgG positive serum when incubated with inactive
complement, resulting in fewer DAPI stained cells (blue). Images are representative of similar staining patterns observed in independent
complement activation assays of the 17 MOG-IgG positive patients (Table 3). Images are shown in 20 × (A-upper panel and B) and 63 × (A-lower
panel) magnification.
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Page 8 of 14Table 3 and additional file 3. Within the group of sub-
jects investigated for CDC, MOG-IgG dependent TCC
formation was found in 2/23 (9%) definite NMO, 5/33
(15%) HR-NMO, 8/19 (42%) ADEM, 1/14 (7%) CIS and
1/14 (7%) CTRL (pediatric patient with genetically con-
firmed citrullinemia with a MOG-IgG serum titer of
1:640). MOG-IgG mediated complement activation did
not correlate with clinical parameters (data not shown),
but was associated with a younger age of the investi-
gated patients (Table 3). In contrast, subjects with lower
MOG-IgG titers and all MOG-IgG negative patients
( N M O ,H R - N M O ,A D E M ,C I S ,M Sa n dC T R L )d i dn o t
activate the complement cascade on the surface of
MOG transfected cells.
Discussion
In this multicenter study we describe for the first time
the presence of serum high-titer MOG-IgG antibodies in
patients with NMO and HR-NMO. Our data confirm
several studies demonstrating the presence of MOG-IgG
in a subgroup of patients with ADEM [24-29], as well as
AQP4-IgG in NMO and HR-NMO [1,2,9,10,12,14,15,32].
Moreover, we report the occurrence of MOG-IgG anti-
bodies in AQP4-IgG seronegative patients with either
NMO (two of two) or HR-NMO (seven of 21), and in
monophasic ON/CIS patients (two of 32). These results
suggest that MOG is a target antigen in AQP4-IgG
negative patients with NMO and HR-NMO, which to
our knowledge has not been described before. This is of
particular relevance since AQP4-IgG is absent in
approximately 5-40% of these patients. This variability of
AQP4 antibody detection could depend on the antibody
assay, the AQP4 isoform, as well as the study population
and/or prior immunosuppressive treatment [9,12,14-16].
However, it has been speculated whether different
pathomechanisms are involved in AQP4-IgG seronegative
NMO and HR-NMO patients compared to subjects with
“AQP4 autoimmune channelopathies”. This assumption is
supported by findings showing no development of NMO-
like symptoms in animals immunized with purified antibo-
dies from AQP4-IgG seronegative NMO patients [33]. In
contrast, antibodies from AQP4-IgG positive NMO
patients were shown to be pathogenic after intra-cerebral
administration combined with human complement [34],
as well as following EAE induction [33,35,36].
An involvement of antibodies directed against MOG in
NMO and HR-NMO is encouraged by in vivo studies
demonstrating the spontaneous development of human
NMO-like symptoms in a double-transgenic mouse strain
with opticospinal EAE [19,20]. Expressing T cell and B cell
receptors specific for MOG, these mice showed inflamma-
tory demyelinating lesions in the optic nerve and spinal
cord, sparing brain and cerebellum [19]. In addition, the
animals harbored a MOG-IgG1 directed humoral immune
Table 3 Patients with CNS demyelinating diseases and controls according to their serum AQP4-IgG and MOG-IgG
mediated complement activation measured by the formation of the terminal complement complex (TCC)
TCC
AQP4-MOG-
TCC
AQP4+MOG-
TCC
AQP4-MOG+
p-value
Number 69 27 17
Females
1 44 (64%) 25 (93%) *§ 11 (65%) 0.017
Disease
2
NMO (n = 23) 6 (26%) 15 (65%) 2 (9%) < 0.001
HR-NMO (n = 33) 17 (52%) 11 (33%) 5 (15%)
ADEM (n = 19) 11 (58%) 0 (0%) 8 (42%)
CIS (n = 14) 12 (86%) 1 (7%) 1 (7%)
MS (n = 10) 10 (100%) 0 (0%) 0 (0%)
CTRL (n = 14) 13 (93%) 0 (0%) 1 (7%)
Age (y)
3 38 (8-74) 48 (19-80) * 13 (2-56) *# < 0.001
AQP4 IgG
1 16 (23%) 27 (100%) *§ 0 (0%) * < 0.001
Titer (1:)
3 0 1,280 *§ 0 < 0.001
(0-1,280) (160-20,480) (0)
MOG IgG
1 7 (10%) 0 (0%) 17 (100%) *# < 0.001
Titer (1:)
3 0 0 2,560 *# < 0.001
(0-2,560) (0-20) (640-20,480)
Patients with NMO (n = 23), HR-NMO (n = 33), ADEM (n = 19), CIS (n = 14), MS (n = 10) and CTRL (n = 14) were grouped according to TCC formation: TCC AQP4
and MOG negative patients (AQP4-MOG-), TCC AQP4 positive and MOG negative (AQP4+MOG-) and TCC AQP4 negative and MOG positive (AQP4-MOG+). In
detail, the antibody serostatus (AQP4-IgG/MOG-IgG) and titer levels of the patients investigated for TCC formation are listed in the additional file 3. P-value:
groups were compared using
1 Fisher’s exact test,
2 Chi-square test and
3 Mann-Whitney U test (data are shown as median with range); * statistically different from
TCC AQP4-MOG-; # statistically different from TCC AQP4+MOG-; § statistically different from TCC AQP4-MOG+ (p-values were corrected for multiple comparisons).
Abbreviations: TCC = terminal complement complex, y = years.
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Page 9 of 14response [19]. Several studies demonstrated the induction
of an NMO-like disease in distinct rat strains following
immunization with MOG [21-23]. However, at present
only limited information is available regarding MOG-IgG
antibodies in human patients suffering from NMO or HR-
NMO symptoms and related disorders. One study
revealed the presence of antibodies directed to the bacte-
rially produced extracellular domain of recombinant
MOG, as investigated with ELISA and immunoblot, in
four NMO patients [30]. However, it was shown that the
detection of antibodies against natively folded MOG is
restricted to assays using MOG expressed on the surface
of cells. In contrast, commonly applied ELISA or Western
blot assays using the bacterially expressed protein failed to
identify these antibodies. This might provide an explana-
tion for the controversial results regarding serum MOG-
IgG antibodies in MS patients. Furthermore, high-titer
MOG-IgG was detected in a subgroup of patients with
pediatric ADEM and MS, but only rarely in adult-onset
MS [24-27,37]. However, these studies did not include
patients with definite and HR-NMO. Most recently, we
could demonstrate high-titer MOG-IgG antibodies in
pediatric patients with recurrent ON (Rostasy K, Mader S,
Schanda K, Huppke P, Gärtner J, Kraus V, Karenfort M,
Tibussek D, Blaschek A, Kornek B, Leitz S, Schimmel M,
Di Pauli F, Berger T, Reindl M: Anti-MOG antibodies in
children with optic neuritis, in press). Now we describe
the presence of MOG-IgG in NMO and HR-NMO. These
findings expand the heterogenous spectrum of MOG-IgG
mediated human demyelinating diseases from ADEM and
pediatric MS to now include AQP4-IgG seronegative
recurrent ON, LETM and NMO. Nevertheless, MOG
might not be the only autoantigen present in AQP4-IgG
seronegative patients with NMO and related disorders.
Recent studies have described antibodies to NMDA-type
glutamate receptors or CV2/CRMP5 in AQP4-IgG serone-
gative cases with NMO or ON [38-40]. Therefore, our
findings of MOG-IgG support a possible relevance of sev-
eral specific CNS autoantigens in AQP4-IgG seronegative
NMO and HR-NMO cases. Further studies are now
required in order to identify potential target antigens.
Several in vitro studies have demonstrated the patho-
g e n i ce f f e c to fA Q P 4 - I g Gi nt h ep r e s e n c eo fa c t i v ec o m -
plement [32,41,42], which is confirmed by our findings of
AQP4-IgG1 mediated CDC at high-titer serum levels of
AQP4-IgG. Furthermore, our results show that antibo-
dies against MOG were primarily of the IgG1 subtype
and could activate the complement cascade in vitro,
resulting in the formation of the TCC on living MOG
transfected HEK-293A cells. To our knowledge, these
observations are novel and might provide a deeper
insight into the role of high-titer serum anti-MOG anti-
bodies. Thus, the detection of high-titer MOG-IgG might
n o to n l ys e r v ea sav a l u a b l eb i o m a r k e ri nA Q P 4 - I g G
negative NMO and HR-NMO patients, but possibly play
a role as pathogenic factor in human demyelinating dis-
eases, although this needs to be further investigated.
There are two limitations that need to be addressed
regarding our study. The first limitation concerns the
usage of an immunofluorescence assay to measure AQP4-
IgG and MOG-IgG antibodies and TCC formation. This is
often criticised by other researchers using automated
assays like flow cytometry or immunoprecipitation for the
measurement of specific antibodies. However, experiences
from the last decades have strongly emphasized that
immunofluorescence assays are the gold standard for the
detection of several autoantibodies, such as anti-nuclear
antibodies. Furthermore, immunofluorescence assays were
shown to yield the highest sensitivity for the detection of
AQP4-IgG [9,14,43-45]. In addition, as an important qual-
ity control in our study, all samples were evaluated by
three independent investigators with 100% concordance
rate. The second limitation concerns the low number of
AQP4-IgG seronegative NMO patients in our study popu-
lation. Nevertheless, we believe that our findings are of
high importance as a substantial proportion of NMO and
HR-NMO patients lack a specific biomarker. Hence, our
results need to be confirmed in a larger study cohort of
AQP4-IgG negative NMO and HR-NMO subjects.
Conclusions
We could show for the first time that AQP4-IgG anti-
body seronegative patients with NMO and HR-NMO
harbor a MOG-IgG directed immune response. MOG is
not a target antigen in “AQP4 channelopathies”,r a i s i n g
the question of whether MOG-IgG positive NMO and
HR-NMO patients share a possible disease overlap with
MOG-IgG positive ADEM. Overall, these results are
highly relevant for clinical practice in order to optimize
patients’ treatment, and might help to elucidate the dis-
ease pathomechanisms of these rare CNS demyelinating
diseases.
Methods
Patients and serum samples
The following patients were recruited from Austria (n =
295), Germany (n = 19), Slovakia (n = 2) and Serbia (n =
19) (Table 1): (1) a total of 45 NMO patients diagnosed
according to the revised diagnostic criteria from Win-
gerchuk et al., 2006 [3], (2) 53 patients with a high risk of
developing NMO (HR-NMO) including 28 monophasic
LETM, 13 recurrent LETM and 12 recurrent ON subjects
[3,10], (3) 33 patients fulfilling the diagnostic criteria for
ADEM [46], (4) 32 CIS patients comprising 19 myelitis
(59%) and 13 ON (41%), (5) 71 patients with MS accord-
ing to the revised “McDonald Criteria” 2005 [47] including
44 patients with relapsing remitting MS, 8 patients with
primary progressive MS and 19 patients with secondary
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Page 10 of 14progressive MS, (6) 101 controls including 24 patients
with OND (stroke, Parkinson’s disease, epileptic seizure,
radiculopathy, insomnia, sleep apnoea syndrome, CNS
lymphoma, traumatic brain injury, myasthenia gravis,
chronic inflammatory demyelinating polyneuropathy, ves-
tibular neuritis, orthostatic syncope, psychogenic neurolo-
gical symptoms, CNS vasculitis, hereditary neuropathy,
analgesic-induced headache, neuroborreliosis, viral ence-
phalitis, chronic tension-type headache, glioblastoma mul-
tiforme), 27 patients with SLE and 50 healthy blood
donors obtained from the central institute for blood trans-
fusion (Central Institute for Blood Transfusion and Immu-
nological Department, Innsbruck University Hospital).
External serum samples were shipped on dry ice to
Innsbruck and all samples were stored at -20°C until
analysis. The present study was approved by the ethical
committee of Innsbruck Medical University (study no.
UN3041 257/4.8, 21.09.2007) and all Austrian patients
or parents/legal guardians gave written informed con-
sent to the study protocol. All Serbian and Slovakian
patients gave their informed consent for serum sampling
and this study was approved by the Institutional Review
Board of the Clinic of Neurology, Clinical Center of Ser-
bia, Belgrade. The Slovakian patients signed the trans-
lated informed consent form of the Innsbruck Medical
University. All German samples were tested anon-
ymously as requested by the institutional review board
of the University of Heidelberg.
AQP4-IgG and MOG-IgG immunofluorescence assays
Analysis of M23 AQP4-IgG was performed using a live
cell staining IF assay as recently described [9,33,48].
HEK-293A cells (ATCC, LGC Standards GmbH, Wesel,
Germany) were transiently transfected (Fugene 6 transfec-
tion reagent, Roche, Mannheim, Germany) using the Vivid
Colours™ pcDNA™ 6.2C-EmGFP-GW/TOPO plasmid
(Invitrogen, Carlsbad, CA, USA), expressing M23 AQP4
fused C-terminally to an emerald green fluorescence pro-
tein (EmGFP). The AQP4-IgG IF assay was performed by
blocking the transfected cells with 4 μg/ml goat IgG
(Sigma-Aldrich, St. Louis, MO, USA) diluted in PBS/10%
FCS (Sigma-Aldrich), subsequently incubating the cells
with pre-absorbed serum samples (rabbit liver powder,
Sigma-Aldrich) at a 1:20 and 1:40 dilution for one hour at
4°C. Bound antibodies were detected using Cy™3-conju-
gated goat anti-human IgG antibody (Jackson ImmunoRe-
search Laboratory, West Grove, PA, USA) for 30 minutes
at room temperature. Dead cells were excluded by DAPI
staining (Sigma-Aldrich). The AQP4-IgG status was deter-
mined using a fluorescence microscope (Leica DMI
4000B, Wetzlar, Germany). Each serum sample was indivi-
dually evaluated by three independent, clinically blinded
investigators (SM, KS and VG), yielding a concordance
rate of 100%.
In order to determine AQP4-IgG titer levels, AQP4-
IgG seropositive samples were further diluted until loss
of specific antibody staining. AQP4-IgG was purified
from a NMO patient’s plasma exchange material as
recently described [33] and served as positive control for
each assay.
Serum MOG-IgG was determined in pre-absorbed
samples using HEK-293A cells transiently transfected
with human MOG cloned into the mammalian expres-
sion vector Vivid Colours™ pcDNA™ 6.2 C-EmGFP/
TOPO (Invitrogen), expressing MOG fused C-terminally
to EmGFP as previously reported [24]. Serum MOG-IgG
was detected on the surface of MOG expressing cells,
using Cy™3-conjugated goat anti-human IgG antibody.
Titer levels were determined for MOG-IgG positive sam-
ples by serial dilution of serum until loss of signal. Based
on our previous results, the cut-off value of high-titer
MOG-IgG antibodies was defined as ≥ 1:160, with 100%
specificity compared to healthy controls [24]. Conse-
quently, in this study patients with titers ≥ 1:160 are
defined as being “high-titer positive”. In contrast, patients
with “low serum antibody reactivity” (1:20-1:80) as well
as serum antibody negative samples (with no detectable
antibodies, titer = 0) were summarized as “negative”
cohort, to simplify the data sets. However, titer levels
below 1:160 are mentioned whenever relevant and illu-
strated in Figure 1. Additionally, antibodies purified from
t h ep l a s m ae x c h a n g em a t e r i a lo fah i g h - t i t e rM O G - I g G
positive ADEM patient were added as a quality control to
each assay. Dead cells were excluded by DAPI staining
and the presence and titer levels of MOG-IgG were ana-
lyzed by three clinically blinded and experienced investi-
gators (SM, KS and VG).
In order to exclude unspecific background staining, we
additionally performed serum antibody stainings using
untransfected HEK-293A cells for both IF assays, trans-
fected cells expressing the fusion protein (EmGFP) as a
control for the AQP4-IgG assay as well as CD2-EmGFP
transfected cells (another protein of the immunoglobulin
superfamily) for the MOG-IgG assay. Non-specific back-
ground binding was clearly distinguishable from a specific
antibody staining in our immunofluorescence setting.
Furthermore, MOG-IgG and AQP4-IgG seropositive
and seronegative control samples are regularly retested
for antibody titer levels to ensure the quality of the test-
ing system. Titer levels remain constant in the serum
samples which are stored at -20°C, even two years after
first analysis.
Determination of IgG1-IgG4 isotypes
Serum antibodies to MOG and AQP4 were analyzed in a
subgroup of 15 patients for IgG1-IgG4 isotypes via our
live cell staining IF assay using MOG or AQP4 trans-
fected cells. After blocking with goat IgG, the transfected
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ples (1:20 and 1:40 dilution) for one hour. Subsequently,
cells were washed and incubated with mouse monoclonal
anti-human IgG1-IgG4 isotype antibodies for 30 minutes
(Sigma-Aldrich, 1:100 dilution in PBS/10% FCS), fol-
lowed by detection using Alexa Fluor
® 546 goat anti-
mouse IgG (Invitrogen) for 30 minutes. Dead cells were
excluded by DAPI staining and analysis was performed
by three independent investigators (SM, KS and VG).
Antibody mediated terminal complement complex (TCC)
in cells expressing AQP4 or MOG
Antibody mediated complement activation was investi-
g a t e di n2 3N M O ,3 3H R - N M O ,1 9A D E M ,1 4C I S ,1 0
MS and 14 CTRL. The selection of patients for the analy-
sis of complement-mediated cytotoxicity was based on the
availability of serum samples and the use of samples which
are representative for our entire study population. Briefly,
serum samples and human complement (Sigma-Aldrich)
were heat-inactivated at 56°C for 45 minutes. Inactivated
serum samples were diluted 1:10 in serum-free X-VIVO
15 medium (Lonza, Verviers, Belgium) and pre-absorbed
with rabbit liver powder. Cells expressing either MOG or
AQP4 were washed three times with X-VIVO 15 medium
and subsequently incubated with heat-inactivated, pre-
absorbed serum samples and 20% active versus 20% heat-
inactivated human complement for 90 minutes at 37°C.
After washing the cells three times with 100 μlX - V I V O
15 medium, detection of TCC formation was performed
by adding the murine-monoclonal anti-human SC5b-9
(Quidel, San Diego, CA, USA; diluted 1:200 in X-VIVO
15) for one hour at 4°C. Following a 30 minutes incuba-
tion with the fluorescence labelled Alexa Fluor
® 546 goat
anti-mouse IgG antibody (1:300, Invitrogen), cells were
washed with PBS/10% FCS and dead cells were visualized
by DAPI staining. All samples were assessed for the pre-
sence of the surface membrane attack complex by three
independent investigators blinded for clinical information
as well as the design of the assay concerning usage of
active/inactive complement (SM, KS and VG).
To analyze the co-localization of the TCC and serum
MOG-IgG or AQP4-IgG, we used HEK-293A cells
expressing MOG or AQP4 without EmGFP fusion
protein.
To obtain M23 AQP4 without EmGFP fusion protein,
the M23 AQP4 isoform was cloned into the pcDNA3.1
Directional TOPO Expression vector (Invitrogen) [9]. In
order to conduct experiments with transfected cells
expressing MOG without EmGFP fusion protein, we
cloned MOG into the pCMV vector (Invitrogen).
Briefly, after incubating the cells with heat-inactivated
samples and active versus inactive complement (90 min-
utes, 37°C), the cells were washed (X-VIVO 15) and
stained with the murine-monoclonal anti-human SC5b-
9 (Quidel, diluted 1:200 in X-VIVO 15 medium, one
hour, room temperature) as described above. Following
three washing steps, the Alexa Fluor
® 488 goat anti-
mouse IgG antibody and Cy™3-conjugated goat anti-
human IgG antibody were diluted in X-VIVO 15 med-
ium and incubated for 30 minutes. Co-staining of
AQP4-IgG and MOG-IgG antibodies (red) and TCC
(green) was investigated in a blinded fashion (SM, KS
and VG), and dead cells were visualized by DAPI stain-
ing. Control experiments using active complement in
the absence of serum showed no TCC formation on
MOG or AQP4 expressing cells (additional file 1 and
additional file 2). Additionally, no cross reaction of the
antibodies to other species than stated was observed.
Scanning electron microscopy (SEM)
AQP4-IgG mediated complement activation was con-
firmed via SEM. Briefly, HEK-293A cells were seeded on
poly-L-lysine (Sigma-Aldrich) coated glass slides (Men-
zel, Braunschweig, Germany) and transiently transfected
with the AQP4-EmGFP vector. Thereafter, serum sam-
ples supplemented with either active or inactive comple-
ment were added to the cells. Following incubation at 37°
C for 90 minutes, the cells were washed with PBS and
fixed in glutaraldehyde (2.5%, v/v in 0.1 m PBS, pH 7.4).
After incubation for 30 minutes at room temperature,
the fixative was replaced by fresh fixative, and incubated
for another two hours at room temperature. Subse-
quently, complement activation was investigated via SEM
according to standard procedures [49]. Samples were
viewed for complement activation in a blinded fashion
using the field-emission SEM DSM982-Gemini (ZEISS,
Oberkochen, Germany).
Statistical analysis
Statistical analysis (means, medians, range, standard
deviations) and significance of group differences were
done using IBM SPSS software (release 18.0, SPSS Inc.,
USA) or GraphPad Prism 5 (GraphPad, San Diego,
USA). Between-group comparisons were performed with
Kruskal-Wallis test, Dunn’s multiple comparison post-
hoc test, Mann-Whitney U test, Fisher’se x a c tt e s ta n d
Chi-square test as appropriate. Correlation of para-
meters was analyzed with Spearman’s non-parametric
correlation. Statistical significance was defined as two-
sided p-value less than 0.05 and Bonferroni’s correction
was applied for multiple comparisons when appropriate.
Additional material
Additional file 1: Complement dependent cytotoxicity on the
surface of AQP4 transfected cells occurs exclusively in AQP4-IgG
positive serum samples. Heat incativated serum samples of patients
with NMO (AQP4-IgG positive), LETM (MOG-IgG positive) and ADEM
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(green) expressing cells in the presence of active complement, and were
analysed for AQP4-IgG mediated complement activation (TCC, red). The
serum of an AQP4-IgG positive NMO patient together with active
complement resulted in TCC formation, and an increased number of
dead cells (blue, DAPI staining). Additionally, we observed a co-
localization of the TCC (red) with the AQP4-EmGFP transfected cells
(green), which is shown in the merged picture of the NMO patient. In
contrast to the NMO patient, AQP4-IgG negative serum samples of
patients with LETM or ADEM did not result in TCC formation in the
presence of active complement. As an additional control, active
complement without serum samples was added, showing no AQP4-IgG
mediated complement activation.
Additional file 2: Complement dependent cytotoxicity on the
surface of MOG transfected cells is restricted to the presence of
serum high-titer MOG-IgG. Heat inactivated serum samples of patients
with NMO (AQP4-IgG positive), LETM (MOG-IgG positive), ADEM (MOG-
IgG positive and negative) were incubated on MOG-EmGFP (green)
transfected cells supplemented with human active complement. MOG-
IgG specific complement activation (TCC, red) was observed using high-
titer MOG-IgG positive sera of a patients with LETM and ADEM.
Furthermore, the TCC co-localized with the MOG-EmGFP transfected cells
(merged), resulting in an increased number of dead cells (blue, DAPI
staining). Serum MOG-IgG negative patients (NMO and ADEM), as well as
active complement (without serum) did not result in TCC formation.
Additional file 3: AQP4-IgG and MOG-IgG serostatus of the patients
(Table 3) investigated for antibody mediated complement
activation. AQP4-IgG or MOG-IgG TCC formation in patients with NMO,
HR-NMO, ADEM, CIS, MS and CTRL, which were subdivided according to
their antibody serostatus: AQP4-IgG positive and MOG-IgG negative
(AQP4+MOG-), AQP4-IgG negative and MOG-IgG seropositive (AQP4-
MOG+) or double negative for AQP4-IgG and MOG-IgG (AQP4-MOG-). *
= The AQP4-MOG- as well as AQP4+MOG- cohort includes patients with
MOG-IgG titer levels below the threshold of 1:160 (cut-off), which are
defined in our study population as MOG-IgG negative. Therefore, MOG-
IgG titer levels below the threshold level are indicated as MOG titer (1:) *.
Antibody titer levels are shown as median titer level (range).
Abbreviation: TCC = terminal complement complex.
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